Cardiovascular risk assessment in type 2 diabetes mellitus Ebaa Al-OzairiR. Jan-Willem MiddelbeekEdward S. Horton OriginalPaper Pages: 333 - 336
Pramlintide: A new tool in diabetes management Laura L. WantRobert E. Ratner OriginalPaper Pages: 344 - 349
Is glycemic variability important to assessing antidiabetes therapies? Boris P. Kovatchev OriginalPaper Pages: 350 - 356
Is the metabolic syndrome a real clinical entity and should it receive drug treatment? Tamara DarsowDavid KendallDavid Maggs OriginalPaper Pages: 357 - 364
How do different GLP-1 mimetics differ in their actions? Simeon Pierre ChoukemJean-FranÇois Gautier OriginalPaper Pages: 365 - 372
Are thiazolidinediones good or bad for the heart? Angela M. TaylorColeen A. McNamara OriginalPaper Pages: 378 - 383
Does a low-fat dietary intervention reduce CVD risk? Sharon D. Jackson Clinical Trials Report Pages: 387 - 388
Orlistat: Current issues for patients with type 2 diabetes Juliet M. Mancino OriginalPaper Pages: 389 - 394
What can the national weight control registry teach us? Elizabeth DaeninckMarsha Miller OriginalPaper Pages: 401 - 404
Interpreting the Joslin diabetes center and joslin clinic clinical nutrition guideline for overweight and obese adults with type 2 diabetes Judy GiustiJo-Anne Rizzotto OriginalPaper Pages: 405 - 408